I have had a number of recent conversations with men with advanced prostate cancer who have been taking Abiraterone Acetate (Zytiga). The question that comes up in regular conversation is about knowing when Zytiga has stopped working or when Zytiga should be discontinued. All the real guidance we have to answer this question comes from [...]
Radium-223 Chloride (Alpharadin) is now available for the treatment of men with advanced prostate cancer who have symptomatic bone metastases (painful) and who are also castration-resistant (hormone-refractory). This is an expanded access program that will allow the use of Alpharadin prior to the formal FDA approval of the treatment. From the Clinical Trials Web Page [...]
GTx Inc. announced that FDA regulators will allow it to restart the clinical trials of its investigational prostate cancer drug Capesaris for men with castrate resistant advanced prostate cancer. They anticipate that the trials of Capesaris will begin during the third quarter of 2012. The trial is designed to evaluate Capesaris as a secondary treatment [...]
For a reason that I can not figure out there are a small but still significant portion of medical studies that automatically exclude gays from participating without an apparent scientific reason. These studies usually have requirements that the subject be in a “reciprocal relationship with a person of the opposite sex." Sometimes the exclusion of [...]
According to recent trials led by The Institute of Cancer Research (ICR) (UK) and The Royal Marsden (UK) combining Zytiga (abiraterone acetate) with the yet FDA unapproved investigational drug MDV3100 could increase the number of men, with advanced prostate cancer, who respond to treatment as well as the length of time they benefit. A new [...]
I am interrupting the reviews of the AACR meeting to inform you of a very important piece of news. Men with advanced prostate cancer which is castrate resistant and who have 2 blaistic bone metastases may now have access to Alpharadin even though the FDA has not yet approved it in the United States! It [...]
Patient Power, a Partner Organization of Malecare, just released a Skype interview they made with me about some aspects of the recent AACR meeting in Chicago. I talk about the exciting results from the Phase II trial of Prostvac, a small phase II study of Pomegranate juice for men with prostate cancer as well as [...]
Curcumin is thought to have anti-cancer activity as well as to provide a synergistic effect with chemotherapy agents. Because of this Dr. Eloise Planchat of the Centre Jean Perrin, Division de Recherche Clinique, EA4231, Université d’Auvergne shared results from a prospective phase II study that assessed the impact of the combination of docetaxel (chemotherapy) plus [...]
From The AACR 2012 Meeting - Does Lycopene Effect Prostate Cancer? Yesterday’s post was about the themes I saw in cancer research. Starting today I will be reporting specific research items I saw at the meeting that specifically are important to men with prostate cancer. Dr. Peter Gann of the University of Illinois at Chicago [...]
According to an article written by Reuters some doctors have raised doubts about the efficacy of Provenge, known scientifically as sipuleucel-T. Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy and the story seems to continue even to today. The current issue has been raised by Marie Huber, a trained scientist [...]
